cyrilzakka/clinical-trials huggingface dataset:
Turkish of the SARS-CoV-2 Anxiety Scale

The coronavirus outbreak has adversely affected individuals in the community, as in the rest of the world. However, in order to carry out this epidemic period in a healthy and conscious manner, determining the anxiety levels of individuals in the society and supporting them psychologically is of great importance. In order to achieve this, healthcare professionals working clinically or academically have important duties. This study was planned to test its validity and reliability in order to adapt the Coronavirus Anxiety Scale to Turkish.

Coronaviruses can be seen in animals and humans as infections that can be mild and severe in society. The SARS-CoV-2 virus, a type of coronavirus, started in China in December 2019 and has spread worldwide as of January 2020. The absence of vaccine and treatment for SARS-CoV-2 disease threatens health worldwide and significantly affects people's daily routine. In China, where the pandemic started, shopping malls and schools were closed for a while, and city entrances and exits were stopped for a while. Although there are similar practices in excellence, as in many countries, measures such as curfew, nursery and school closure continue to be taken for under-20s and over-65s. . The coronavirus epidemic that affects our entire life is not fully known about the disease process, WHO is defined as the pandemic of the epidemic, the nearest contact is the greatest risk of transmission, and the loss of many lives during this process affects all individuals in the society negatively and increases the level of anxiety .

It is a psychological reaction involving many emotions such as anxiety, stress, or anxiety, fear and distress that arise in a situation that threatens the safety of the individual. Conditions such as uncertainty, various diseases (cancer, epidemic, etc.) and losing a relative can cause anxiety. Outbreaks that occur suddenly and are at risk of death are among these reasons.

Eligibility Criteria:
inclusion criteria;

* individuals agree to participate in the study
* 18 years old,
* Lack of visual obstacle,
* Knowing how to speak, read and write in Turkish.

Exclusion criteria;

* individuals refuse to participate in the study
* 18 years old,
* Visually impaired,
* Does not know how to speak, read and write in Turkish
Comparison Of Different Orthodontic Aligner Systems Applied On Single Stage And Three Stage

Applying to the Orthodontics Department of the Faculty of Dentistry of Erciyes University for orthodontic treatment, a periodontally healthy 16-26 year-old periodontally healthy, non-congenital or congenital anomaly in the craniofacial region; 25 patients with class 1 orthodontic malocclusion with moderate permeability will be included in the study. The patients will be divided into 2 groups, and the first group of 12 patients will have single-stage aligner; The second group of 13 patients is planned to apply 3-stage aligner.

It is planned to take lateral cephalometric radiography, panoramic radiography before and after the orthodontic treatment, and in addition to orthodontic model and photograph records before, during and after the treatment. Patient comfort and satisfaction will be evaluated by applying questionnaires to patients before treatment, immediately after starting treatment, 2 days later, 1 week later, 1 month later, 1 week before and after the treatment, and the effects of 2 different treatment methods on the patients will be evaluated according to the data obtained. QLF recordings are also taken at the beginning of treatment and at 3-month intervals, and the effects of single plaque use and 3 different plaque use on white spot lesion formation will be evaluated.

Hays Nance analysis will be used in the orthodontic models to determine the change in the amount of perplexity. In this way, tooth movement speeds can be determined. There are studies in the literature with single-stage transparent plates, but there are no studies with different-stage plates. In our study, which of the two different types of treatment is more comfortable on patients and affects the movement of teeth faster; In addition, the investigators plan to investigate which one has a low risk of white spot lesions on the teeth.

Eligibility Criteria:
Inclusion Criteria:

* No systemic disease
* Being healthy as periodontal.
* No smoking.
* No previous orthodontic treatment.
* Lack of congenital tooth deficiency
* Permanent dentition
* Class 1 malocclusion
* No clefts
* No extracted teeth

Exclusion Criteria:

* Orthodontic treatment history
* Missing tooth
* Poor oral hygiene
* Lack of cooperation
A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds

As this is a proof-of-concept study, the primary objective is to provide preliminary data on the safety and efficacy of Bioresorbable Wound Scaffold in the management of acute wounds left to heal by secondary intent.


Eligibility Criteria:
Inclusion Criteria:

* Subjects over 18 years, willing and able to provide written informed consent.
* Subjects who have an excised pilonidal sinus wound left to heal by secondary intent.
* Subjects who are willing to commit to having two biopsies being taken during the study.

Exclusion Criteria:

* Subjects with a history of skin sensitivity to any of the components of the study product
* Subjects whose wound is infected
* Subjects who have participated in a previous clinical study within the past 3 months
* Subjects' with a known history of poor compliance with medical treatments
* Subjects who are pregnant (where pregnancy is a possibility, a pregnancy testing kit will be provided)
* Necrotic/sloughy wounds unless surgically debrided prior to enrolment
* Medical or emotional risk associated with the potential biopsy that outweighs the risk of not taking a biopsy as determined by the investigator
* Subjects exhibiting any other medical condition which, according to the Investigator, justifies the subject's exclusion from the study
* Subjects with impaired renal function
Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: a Randomized Trial

Rationale: With improvements in systemic tumour-directed treatments for primary tumours, survival rates for patients with bone metastases are improving. However, individual illness trajectories become less predictable and more vulnerable to adverse events from treatments, negatively impacting a patient's quality of life (QoL). Palliative care is aimed at reducing symptoms and improving QoL for patients with incurable diseases through early identification, thorough assessment, and effective management of physical, psychological, social, and spiritual challenges. Early integration of specialist palliative care into oncology care has shown to reduce symptom burden and potentially inappropriate end-of-life care, and to enhance QoL, yet it is often initiated late.

Objective: The primary objective is to evaluate the satisfaction with care and QoL experienced by patients with bone metastases who are offered a consultation with the hospital palliative care consultation team (PCCT) when referred for palliative radiotherapy compared to patients who receive standard of care.

Study design: A prospective, pragmatic, two-arm multicenter randomized controlled trial within the PRospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT+) cohort that follows the Trials within Cohorts (TwiCs) design.

Study population: Patients with bone metastases referred for palliative radiotherapy who have their treating physician in one of the participating centers and have not been in contact with the hospital PCCT before.

Intervention: A consultation with the hospital PCCT within two weeks after inclusion in PRESENT+. In the standard of care control group, no consultation with the PCCT will be scheduled. They may have a consultation during follow-up if referring physicians may consider a consultation appropriate, or when patients themselves feel they want a referral.

Main study parameters/endpoints: Satisfaction with care (affective behavior) four weeks after inclusion in PRESENT+.


Eligibility Criteria:
Inclusion Criteria:

1. broad informed consent for PRESENT+ (i.e., consent for filling out questionnaires at regular intervals and randomization into future intervention studies), and
2. having their treating physician in the TIPZO-RT study site (UMC Utrecht, Radboudumc or LUMC).

Exclusion Criteria:

1. not able to understand the objective of the study (in Dutch),
2. cognitive impairment or dementia, and
3. has been in contact with palliative care consultants of the hospital PCCT before.
Evaluation of a Pathway on the Evolution of Renal Function in Patients With Advanced Chronic Kidney Disease

The number of incident and prevalent patients with end stage renal disease on dialysis treatment is increasing in France and worldwide. A quarter of dialysis patients are initiating dialysis urgently through central venous catheters and the number of patients registered in the waiting list for renal transplantation before dialysis initiation is very low. This is also reflected in the very low number of pre-emptive renal transplantations.

In order to reduce the number of dialysis patients, the French state has induced a national program proposing a multidisciplinary care pathway including the nephrology visits and at least one consultation with a dietitian and a specialist renal nurse in all patients with Chronic Kidney Disease stage 4 and 5.

The aim of this single-center retrospective study is to evaluate the influence of the complete, partial or no participation in this program on the evolution of renal function and clinicobiological parameters in this group of patients.


Eligibility Criteria:
Inclusion Criteria:

* All stage 4 and 5 Chronic Kidney Disease patients that were included in the program from 01/01/2021 to 31/12/2021 in the clinics of AURA SANTE

Exclusion Criteria:

* Patients without a medical follow up during this year (2021)
* Patients with insufficient or no data during the 24 month of follow up period
* Active treatment with corticosteroids, cytotoxic or immunosuppressive drugs, ongoing infection, autoimmune disease or active tumor process
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

This study is a Phase 2, randomized, double-blind, placebo-controlled, single-center study in adult patients with type 2 diabetes. It will evaluate the safety and tolerability of oral GLY-200. Subjects will participate in a ≤ 18-day screening period followed by a metformin washout period of approximately 14 days, and an inpatient period of 16 days. Approximately 48 subjects will be randomized to 1 of 3 active treatment groups or 1 of 3 placebo groups. Dosing will occur for 14 days. A follow-up clinic visit will occur on Day 21 \[End of Study (EOS)\] or Early Termination (ET).


Eligibility Criteria:
Key Inclusion Criteria:

* Patients diagnosed with type 2 diabetes: hemoglobin A1c (HbA1c)) ≥ 6.0 and ≤ 8.5% at screening
* Body mass index (BMI) ≥ 18 and ≤ 40 at screening

Key Exclusion Criteria:

* Treated with any prescription medication for the treatment of type 2 diabetes or weight loss other than metformin in the last 3 months prior to screening
* Use of any drug treatment that affects gastric pH
* Use of any drug treatment that affects gastrointestinal motility
* Fasting blood glucose \> 190 mg/dL
* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract or active disease within 12 months prior to screening
* History of any previous abdominal or intestinal surgery including endoscopic, open or laparoscopic thoracic or abdominal surgery, surgical resection of the stomach, small or large intestine
* Clinically significant medical condition as judged by the Investigator that could potentially affect study participation and/or personal well-being
The Expression Heparanase in Term and Preterm Placentas

Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM).

This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) .

The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.


Eligibility Criteria:
Inclusion Criteria:

* Singleton pregnancy

Exclusion Criteria:

* High-risk patients
* Multiple pregnancy
* Significant maternal illness
* Significant fetal anomaly
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy


Eligibility Criteria:
Inclusion Criteria:

* biopsy proved nasopharyngeal carcinoma;
* stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
* 18 years or older; without other malignancy;
* proper functioning of the major organs.

Exclusion Criteria:

* allergic to anlotinib;
* female within gestation period or lactation;
* patients received drug of other clinical trial within 4 weeks.
Randomized Study Comparing Fluoroscopically-Guided Versus Blinded Trochanteric Bursa Injections

The goals of our research project are to study the relationship, if any, between the success of a TB injection (measured by pain relief and general patient satisfaction) and the method in which it was placed. Because fluoroscopy places patients requires a slight risk from radiation exposure and increased cost versus blind injection, it is important to know if there is an advantage to using this technique. The investigators will randomize 64 patients to receive either trochanteric bursa injections with corticosteroid and local anesthetic guided by fluoroscopy, or trochanteric bursa patients to receive trochanteric bursa injections based on landmarks on palpation. The investigators will then determine which method is superior, and whether injecting steroid and local anesthetic into the bursa itself is superior or inferior to injecting it into a tender area outside the bursa.

This will be a randomized, controlled study evaluating the value of fluoroscopy in trochanteric bursa injections. Subjects will be recruited solely from the patients we normally see at the Blaustein Pain Treatment Center with a clinical diagnosis of GTPS. Sixty-four patients will be randomized in a 1:1 ratio using sealed envelopes to receive either TB corticosteroid injection done blind or with fluoroscopy. All patients who provide informed consent will be brought into the fluoroscopy suite and placed in the lateral decubitus position. In the patients randomized to receive fluoroscopically guided injections, a 22-gauge needle will be placed into the TB and correct position confirmed by fluoroscopy and contrast injection (1 ml per attempt) before corticosteroid and local anesthetic injection (60 mg of depomedrol and 2.5 ml of 0.5% bupivacaine). In the blinded group, one sham, pulsed fluoroscopic image will be taken of the femur, and the injection will be done based only on physical exam (overlying the area of maximal tenderness) and landmarks. Prior to the injection, 1 ml of contrast will be administered and another image taken to determine whether or not the needle is within the bursa, but this will not alter the injection. After contrast administration, the same corticosteroid and bupivacaine injection will be administered. The 2 main questions we propose to answer are: 1) whether using fluoroscopy for TB injections results in improved outcomes (comparison of the 32 patients in each group); and 2) whether injecting into the bursa provides superior results than performing non-bursal injections into the area of maximal tenderness (comparison of 32 patients who receive fluoroscopically-guided bursa injections + those patients whose blinded injection was noted to be intra-bursal vs. those patients whose blinded injection was extra-bursal).

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Clinical diagnosis of trochanteric bursitis

Exclusion Criteria:

* Pregnancy
* Allergy to contrast
* Untreated coagulopathy
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis free survival (DMFI) as a primary endpoint.

Arm A: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a week i.v followed by 48 weeks of treatment with 3 x 10 MIU/m2 s.c Arm B: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a week i.v repeated 3 times with 12 treatment-free-weeks between the cycles

Secondary endpoints: Improved overall survival rate, Assess side effects of therapy in both treatment arms, Assess time spent on sick leave, Assess number of treatment-related days in hospital, Assess overall performance status, Assess blood MX protein levels

Eligibility Criteria:
Inclusion Criteria:

* Histological documentet cutaneous malognant melanoma
* Stage IIIa, IIIb, IIIc (AJCC 2002)
* R0 resection dating back no longer than 56 days
* Performance status (ECOG o-1)
* Bone marrow funktion: White cell count \> 3000 cells/ul, platletts \> 100000 cells/ul, hemoglobin \> 10 g/dl
* Liver and kidney funktion: Serum creatinin \< 1.5 times upper limit of normal, AST and ALT \< 2.5 times upper limit of normal, Serum bilirubin \< 2 times upper limit of normal
* Written inform consent

Exclusion Criteria:

* Confirmed distant metastasis
* Choroid or mucosal melanoma
* Pregnant or lactating women and women of childbearing potential not using a reliable form of contraception
* Active autoimmun disease
* patients with history of neuropsychiatric disease requiring hospitalization
* Severe medical condition such us:
* Florid hepatitis
* Severe acute infection
* Myocardial infarction within the past year,symptomatic angina pectoris
* Grade III to IV congestive heart failure
* serious pulmonary disease
* HIV-positive patients with an AIDS - defining condition
* treatment in another clinical drug trial within the last 30 days
* A history of hypersensitivity to interferon alfa
* History of maignant disease during the past 5 years (except for curatively treated skin carcinoma or in situ carcinoma)
* Prior high dose interferon alfa therapy.Prior adjuvant low dose or intermediate-dose interferon alfa therapy is allowed
Pilot Study for PET/MR Imaging of Covid-19

The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.

This study is a non-randomized non-treatment study. The intention of this work is an assessment of the PET insert technology, and not, for example, to perform a treatment assessment or drug assessment. This work will actively recruit 10 individuals (5 Covid-19 negative and 5 Covid-19 previously positive in the last 180 days) to perform imaging of the brain with an FDA-approved radiotracer.

Eligibility Criteria:
Inclusion Criteria:

1. Whole body radiation dose in the last year of less than 5000 mrem determined via subject verbal history reporting
2. Must be at least 21 years of age
3. Deemed healthy to endure duration of imaging study as confirmed via study PI
4. Proof of COVID-19 viral or antibody testing within the timeframe of \>20 days but \<=180 days prior to scan.

Exclusion Criteria:

1. History of non-MRI compatible surgeries, implants, or activities
2. Pregnant or nursing
3. History of allergic reactions to PET radiotracers (via patient verbal report and /or medical record review.
Diagnostic Value of Shear-Wave Elastography for Patellar Tendinopathy

To investigate the accuracy of shear-wave elastography (SWE) in diagnosing patellar tendinopathy in female volleyball and basketball players. In addition, we want to compare different parts of the patellar tendon and investigated the effects of different knee angles.


Eligibility Criteria:
Inclusion Criteria were:

* being a female athlete between the ages of 17-35 playing professional basketball or volleyball and agreeing to participate in the study

Exclusion Criteria were:

* to have a history of partial or full-thickness patellar tendon tear,
* if they received an injection in or around the patellar tendon within the past 12 months,
* undergone patellar tendon graft repair for anterior cruciate ligament, had a ligament or meniscus operation within the past six months,
* have a chronic disease (such as diabetes, heart disease, or rheumatic disease),
* are actively using oral contraceptives,
* have an active infection in the knee or surrounding tissues
Study Evaluating the Safety and Tolerability of NSA-789

This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.


Eligibility Criteria:
Inclusion:

* Healthy men and women between 18 and 50 years old.
* Women must be of non-child-bearing potential (not able to have children).
* Must be of normal body weight.
Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)

This is a multicenter hospital-based prospective cohort study conducted in institutions with known expertise in performing oocytes/embryo freezing for fertility preservation. The study aims at refining the understanding of the efficacy and safety of controlled ovarian stimulation with or without letrozole in young women with newly diagnosed breast cancer who are candidates to receive (neo)adjuvant chemotherapy.

Patients enrolled in this study undergo standard or "random start" ovarian stimulation with Gonadotropins using antagonist protocol before the beginning of chemotherapy. Ovulation is triggered in all patients with a Gonadotropin Releasing Hormone-GnRH agonist.

After retrieval, oocytes are denuded and matured oocytes are subjected to fertilization before embryo freezing or direct vitrification.

Primary objective is to evaluate the efficacy of performing a controlled ovarian stimulation with or without letrozole in young women with newly diagnosed breast cancer who are candidates to receive (neo)adjuvant chemotherapy in terms of mature oocytes collected.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of invasive non-metastatic breast cancer (i.e. stage I to III);
* Breast cancer diagnosis ≥18 and ≤ 40 years;
* No prior history of gonadotoxic treatments;
* Fertility preservation counseling for fertility preservation;
* Written inform consent;
* FSH \< 20 UI/L and/or antra-follicular count ≥ 6 (follicles of 2-9 mm) and/or AMH ≥ 6 pmol (only applicable for patients who undergo controlled ovarian stimulation for embryo/oocyte cryopreservation).

Exclusion Criteria:

* Newly diagnosed stage IV breast cancer (i.e. de novo metastatic breast cancer);
* Prior diagnosis of other malignancies before breast cancer.